Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double-Blind
Body weight
William Polvino, MD
Study Director
Helsinn Therapeutics (U.S.), Inc
United States: Food and Drug Administration
RC-1291-205
NCT00267358
November 2005
October 2006
Name | Location |
---|---|
South Carolina Oncology Associates | Columbia, South Carolina 29201 |
Kenmar Research Institute | Los Angeles, California 90057 |
Charleston Cancer Center | Charleston, South Carolina 29406 |
PAB Clinical Research | Brandon, Florida 33511 |
Hematology Oncology Consultants, Inc. | Columbus, Ohio 43235 |
Bay Area Oncology | Tampa, Florida 33607 |
Center for Cancer and Blood Disorders | Bethesda, Maryland 20817 |
Multicare Health System | Tacoma, Washington 98415 |
South Carolina Cancer Specialists | Hilton Head Island, South Carolina 29925 |
Pacific Oncology & Hematology Associates | Encinitas, California 92024 |
Melbourne Internal Medicine Associates | Melbourne, Florida 32901 |
Pacific Oncology and Hematology Associates | San Diego, California 92024 |
Palo Verde Hematology Oncology Ltd. | Glendale, Arizona 85304 |
Comprehensive Blood & Cancer Center | Bakersfield, California 93309 |
Advanced Medical Research Institute | Fresno, California 93710 |
Kenmar Clinical Research | Los Angeles, California 90057 |
Sant Chawla, Inc. | Santa Monica, California 90403 |
Osler Medical, Inc./ Osler Clinical Research | Melbourne, Florida 32901 |
University of Texas Medical Texas | Galveston, Texas 77555 |